A medication used to treat asthma and eczema can improve survival rates for patients with moderate to severe COVID-19, a clinical trial conducted at UVA Health suggests.
Aug 11, 2022
0
92
Long-term treatment of severe asthma with dupilumab supports sustained reduction in oral corticosteroid (OCS) dosage and improvement in clinical end points for up to 96 weeks, according to a study published in the July issue ...
Jul 22, 2022
0
12
A new medication has been added to the treatment options for children with moderate-to-severe asthma. In a late-stage clinical trial, the biologic agent dupilumab reduced the rate of severe asthma attacks and improved lung ...
Dec 8, 2021
0
33
(HealthDay)—Dupilumab is associated with significantly reduced severe exacerbation rates in patients with late-onset asthma with or without fixed airway obstruction, according to a study presented at the American Thoracic ...
May 21, 2019
0
1
